Mirati Therapeutics, Inc

Neurelis, Inc. is a San Diego-based pharmaceutical company specializing in the development and commercialization of innovative therapies for neurological disorders. With a strong focus on medical affairs and research, Neurelis is dedicated to providing personalized support for patients and care partners. Their pipeline includes NRL-1049 and NRL-4, utilizing advanced science and technologies to address unmet medical needs in the field. As a leader in the industry, Neurelis collaborates with strategic partners to advance their mission of improving patient outcomes. With a commitment to ethical business conduct, Neurelis is known for its dedication to community involvement and the highest standards of quality. Their trademarks, including VALTOCO and MYNEURELIS, represent their commitment to innovation and excellence in the field of neurological therapeutics.Generated from the website

Travere Therapeutics, Inc. is a San Diego-based biopharmaceutical company focused on developing life-changing therapies for individuals living with rare diseases, particularly in the fields of rare kidney and metabolic disorders. The company is dedicated to advancing science that has the potential to set new standards of care and improve patients' lives. With a strong commitment to patient advocacy, Travere engages with the community through initiatives like the "Play It Forward" campaign, aimed at raising awareness for conditions such as Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy (IgAN). Their mission is driven by the needs of patients, caregivers, and advocates, emphasizing resilience and support within the rare disease community. Generated from the website

Evofem Biosciences, Inc., based in San Diego, CA, is pioneering advancements in women's sexual and reproductive healthcare with its innovative, hormone-free contraceptive product, Phexxi. Launched in 2020, Phexxi is a localized, on-demand prescription contraceptive that empowers women to take control of their reproductive health by allowing usage up to 60 minutes before intercourse. The company is addressing a significant market opportunity, as an estimated 23 million women in the U.S. are not using hormonal contraceptives. With the growing preference for non-hormonal options, Phexxi provides a viable alternative for women seeking to avoid side effects associated with traditional hormonal birth control, thereby fulfilling an important unmet need in the contraceptive space. Generated from the website